Tonix Pharmaceuticals (TNXP) announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute, KEMRI, to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 as a vaccine to prevent mpox and smallpox. Tonix will be the sponsor and KEMRI will lead the execution of the proposed clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals (TNXP) Q3 Earnings Cheat Sheet
- Tonix Pharma Showcases Promising TNX-801 Vaccine Results
- Tonix Pharmaceuticals presents data on TNX-801 at World Vaccine Congress
- Tonix Pharma Secures Defense Contract for Antiviral Development
- Tonix Pharmaceuticals receives first contract payment from U.S. DoD